Adlea capsaicin: Phase III data

The double-blind, U.S. Phase III ACTIVE-1 trial in 301 patients showed that Adlea missed the primary endpoint of reducing post-surgical pain as measured by a time-weighted pain score at 4 to 32 hours ...